{"id":861135,"date":"2023-02-07T18:07:36","date_gmt":"2023-02-07T17:07:36","guid":{"rendered":"https:\/\/bebeez.it\/non-categorizzato\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/"},"modified":"2023-02-07T18:07:36","modified_gmt":"2023-02-07T17:07:36","slug":"tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials","status":"publish","type":"post","link":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/","title":{"rendered":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials"},"content":{"rendered":"HELSINKI--(BUSINESS WIRE)--TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland\u2019s Lifeline Ventures, an early-stage venture capital firm founded by serial entrepreneurs.\n\n\n\nThe funding will be used to advance to Phase II the company\u2019s combination trials which use oncolytic immunotherapies synergistically with checkpoint inhibitors.\n\n\nThis final close of \u20ac12 million includes \u20ac5.9 million equity from the European Innovation Council (EIC) Fund as well as a \u20ac2.1 million grant from EIC\u2019s Accelerato
Abbonati<\/a> o Accedi<\/a> per leggere il resto di questo contenuto.<\/div><\/div>","protected":false},"excerpt":{"rendered":"

HELSINKI–(BUSINESS WIRE)–TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland\u2019s Lifeline Ventures, an early-stage venture capital firm founded by serial […]<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[49624],"tags":[],"settori":[],"slider_categorie_and_home_page":[],"class_list":["post-861135","post","type-post","status-publish","format-standard","hentry","category-private-capital-in-europe"],"acf":[],"yoast_head":"\nTILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez\" \/>\n<meta property=\"og:description\" content=\"HELSINKI--(BUSINESS WIRE)--TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland\u2019s Lifeline Ventures, an early-stage venture capital firm founded by serial […]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\" \/>\n<meta property=\"og:site_name\" content=\"BeBeez\" \/>\n<meta property=\"article:published_time\" content=\"2023-02-07T17:07:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png\" \/>\n\t<meta property=\"og:image:width\" content=\"683\" \/>\n\t<meta property=\"og:image:height\" content=\"242\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials\",\"datePublished\":\"2023-02-07T17:07:36+00:00\",\"dateModified\":\"2023-02-07T17:07:36+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\"},\"wordCount\":818,\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"articleSection\":[\"Private capital in Europe\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\",\"url\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\",\"name\":\"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez\",\"isPartOf\":{\"@id\":\"https:\/\/15.161.165.86\/#website\"},\"datePublished\":\"2023-02-07T17:07:36+00:00\",\"dateModified\":\"2023-02-07T17:07:36+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/bebeez.it\/en\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/15.161.165.86\/#website\",\"url\":\"https:\/\/15.161.165.86\/\",\"name\":\"BeBeez\",\"description\":\"BeBeez\",\"publisher\":{\"@id\":\"https:\/\/15.161.165.86\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/15.161.165.86\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/15.161.165.86\/#organization\",\"name\":\"BeBeez\",\"url\":\"https:\/\/15.161.165.86\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"contentUrl\":\"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png\",\"width\":309,\"height\":122,\"caption\":\"BeBeez\"},\"image\":{\"@id\":\"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/","og_locale":"en_US","og_type":"article","og_title":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez","og_description":"HELSINKI--(BUSINESS WIRE)--TILT Biotherapeutics (TILT), a clinical-stage biotechnology company developing cancer immunotherapies, announces the final close of its EUR 22 million (approximately USD 23.8 million) round. This follows on from the first close of EUR 10 million in June 2022. The financing was led by Finland\u2019s Lifeline Ventures, an early-stage venture capital firm founded by serial […]","og_url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/","og_site_name":"BeBeez","article_published_time":"2023-02-07T17:07:36+00:00","og_image":[{"width":683,"height":242,"url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo-x2.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#article","isPartOf":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/"},"author":{"name":"","@id":""},"headline":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials","datePublished":"2023-02-07T17:07:36+00:00","dateModified":"2023-02-07T17:07:36+00:00","mainEntityOfPage":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/"},"wordCount":818,"publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"articleSection":["Private capital in Europe"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/","url":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/","name":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials - BeBeez","isPartOf":{"@id":"https:\/\/15.161.165.86\/#website"},"datePublished":"2023-02-07T17:07:36+00:00","dateModified":"2023-02-07T17:07:36+00:00","breadcrumb":{"@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/bebeez.it\/en\/private-capital-in-europe\/tilt-biotherapeutics-announces-final-close-of-e22-million-financing-round-to-advance-to-phase-ii-oncology-immunotherapy-trials\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/bebeez.it\/en\/"},{"@type":"ListItem","position":2,"name":"TILT Biotherapeutics Announces Final Close of \u20ac22 Million Financing Round to Advance to Phase II Oncology Immunotherapy Trials"}]},{"@type":"WebSite","@id":"https:\/\/15.161.165.86\/#website","url":"https:\/\/15.161.165.86\/","name":"BeBeez","description":"BeBeez","publisher":{"@id":"https:\/\/15.161.165.86\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/15.161.165.86\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/15.161.165.86\/#organization","name":"BeBeez","url":"https:\/\/15.161.165.86\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/","url":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","contentUrl":"https:\/\/bebeez.it\/wp-content\/uploads\/2019\/10\/be-beez-logo.png","width":309,"height":122,"caption":"BeBeez"},"image":{"@id":"https:\/\/15.161.165.86\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/861135","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/comments?post=861135"}],"version-history":[{"count":0,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/posts\/861135\/revisions"}],"wp:attachment":[{"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/media?parent=861135"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/categories?post=861135"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/tags?post=861135"},{"taxonomy":"settori","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/settori?post=861135"},{"taxonomy":"slider_categorie_and_home_page","embeddable":true,"href":"https:\/\/bebeez.it\/en\/wp-json\/wp\/v2\/slider_categorie_and_home_page?post=861135"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}